Spotlight on the Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism is Keeping the Highest Risk From Antithyroid Drugs in the Blind Spot

Mark Tulchinsky, A. Bertrand Brill

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

July 1, 2019, JAMA Internal Medicine released online an article authored by Kitahara et al entitled "Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism." The Altmetric Attention Score, a global indicator of interest from lay public and colleagues, skyrocketed to 223 by July 7, placing the article in the top 5% of all scored reports. The overall perception of death from cancer risk associated with I is inflated and not supported by evidence. As co-authors of this article, we offer previously unpublished data and analysis that (1) disputes clinical significance of the associated risk from I and (2) shows, again, that antithyroid drugs carry a statistically significant and a much more obvious cancer death risk.

Original languageEnglish (US)
Pages (from-to)789-791
Number of pages3
JournalClinical nuclear medicine
Volume44
Issue number10
DOIs
StatePublished - Oct 1 2019

Fingerprint

Antithyroid Agents
Optic Disk
Hyperthyroidism
Iodine
Mortality
Neoplasms
Dissent and Disputes
Internal Medicine
Therapeutics

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

@article{bc5c5a4e280e47b99b0bc471d8b59ac6,
title = "Spotlight on the Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism is Keeping the Highest Risk From Antithyroid Drugs in the Blind Spot",
abstract = "July 1, 2019, JAMA Internal Medicine released online an article authored by Kitahara et al entitled {"}Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism.{"} The Altmetric Attention Score, a global indicator of interest from lay public and colleagues, skyrocketed to 223 by July 7, placing the article in the top 5{\%} of all scored reports. The overall perception of death from cancer risk associated with I is inflated and not supported by evidence. As co-authors of this article, we offer previously unpublished data and analysis that (1) disputes clinical significance of the associated risk from I and (2) shows, again, that antithyroid drugs carry a statistically significant and a much more obvious cancer death risk.",
author = "Mark Tulchinsky and Brill, {A. Bertrand}",
year = "2019",
month = "10",
day = "1",
doi = "10.1097/RLU.0000000000002792",
language = "English (US)",
volume = "44",
pages = "789--791",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Spotlight on the Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism is Keeping the Highest Risk From Antithyroid Drugs in the Blind Spot

AU - Tulchinsky, Mark

AU - Brill, A. Bertrand

PY - 2019/10/1

Y1 - 2019/10/1

N2 - July 1, 2019, JAMA Internal Medicine released online an article authored by Kitahara et al entitled "Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism." The Altmetric Attention Score, a global indicator of interest from lay public and colleagues, skyrocketed to 223 by July 7, placing the article in the top 5% of all scored reports. The overall perception of death from cancer risk associated with I is inflated and not supported by evidence. As co-authors of this article, we offer previously unpublished data and analysis that (1) disputes clinical significance of the associated risk from I and (2) shows, again, that antithyroid drugs carry a statistically significant and a much more obvious cancer death risk.

AB - July 1, 2019, JAMA Internal Medicine released online an article authored by Kitahara et al entitled "Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism." The Altmetric Attention Score, a global indicator of interest from lay public and colleagues, skyrocketed to 223 by July 7, placing the article in the top 5% of all scored reports. The overall perception of death from cancer risk associated with I is inflated and not supported by evidence. As co-authors of this article, we offer previously unpublished data and analysis that (1) disputes clinical significance of the associated risk from I and (2) shows, again, that antithyroid drugs carry a statistically significant and a much more obvious cancer death risk.

UR - http://www.scopus.com/inward/record.url?scp=85071788586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071788586&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000002792

DO - 10.1097/RLU.0000000000002792

M3 - Article

C2 - 31453816

AN - SCOPUS:85071788586

VL - 44

SP - 789

EP - 791

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 10

ER -